Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortiumDanelle F James, Lillian Werner, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib TherapyJennifer A Woyach, Paolo Ghia, John C Byrd, et al.
JAMA Oncology|February 23, 2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical TrialsSusan M O'Brien, Samantha Jaglowski, John C Byrd, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
Blood|September 20, 2017
Ibrutinib for chronic graft-versus-host disease after failure of prior therapyDavid Miklos, Corey S Cutler, Mukta Arora, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Blood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
American Journal of Hematology|February 16, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisSusan M O'Brien, John C Byrd, Peter Hillmen, et al.
Pageof 4